Lisocabtagene maraleucel, also known as liso-cel and JCAR017 is a 4-1BB-based second generation CAR-T therapy, that contains a distinct IgG4-based hinge. The therapy is a key pipeline asset which Bristol-Myers picked up through its takeover […]
Artisan bio entered into a gene editing research agreement with Cabaletta, which allows it to integrate Artisan’s advanced gene editing and engineering technology into Cabeletta’s next-generation CAAR T products as the company continues to expand […]
A clinical stage biotechnology company developing a new class of biologics, Human Heavy-Chain Antibodies (UniAb), Teneobio and a leading genome editing company focused on developing proprietary curative therapeutics using the CRISPR/Cas9 system i.e Intellia therapeutics […]
Get In Touch
